Bioactivation of tamoxifen by recombinant human cytochrome P450 enzymes

被引:46
作者
Notley, LM [1 ]
de Wolf, CJF [1 ]
Wunsch, RM [1 ]
Lancaster, RG [1 ]
Gillam, EMJ [1 ]
机构
[1] Univ Queensland, Sch Biomed Sci, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia
关键词
D O I
10.1021/tx0100439
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tamoxifen is a major drug used for adjuvant chemotherapy of breast cancer; however, its use has been associated with a small but significant increase in risk of endometrial cancer. In rats, tamoxifen is a hepatocarcinogen, and DNA adducts have been observed in both rat and human tissues. Tamoxifen has been shown previously to be metabolized to reactive products that have the potential to form protein and DNA adducts. Previous studies have suggested a role for P450 3A4 in protein adduct formation in human liver microsomes, via a catechol intermediate; however, no clear correlation was seen between P450 3A4 content of human liver microsomes and adduct formation. In the present study, we investigated the P450 forms responsible for covalent drug-protein adduct formation and the possibility that covalent adduct formation might occur via alternative pathways to catechol formation. Recombinant P450 3A4 catalyzed adduct formation, and this correlated with the level of uncoupling in the P450 incubation, consistent with a role of reactive oxygen species in potentiating adduct formation after enzymatic formation of the catechol metabolite. Whereas P450s 1AI, 2D6, and 3A5 generated catechol metabolite, no covalent adduct formation was observed with these forms. By contrast, P450 2136, 2C19, and rat liver microsomes catalyzed drug-protein adduct formation but not catechol formation. Drug protein adducts formed specifically with P450 3A4 in incubations using membranes isolated from bacteria expressing P450 3A4 and reductase, as well as in reconstitutions of purified 3A4, suggesting that the electrophilic species reacted preferentially with the P450 enzymes concerned.
引用
收藏
页码:614 / 622
页数:9
相关论文
共 43 条
[1]   Oxidation kinetics of ethanol by human cytochrome P450 2E1 - Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b(5) on steady-state kinetics [J].
Bell, LC ;
Guengerich, FP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) :29643-29651
[2]   Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes [J].
Crewe, HK ;
Ellis, SW ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :171-178
[3]  
Cuttle L, 2000, DRUG METAB DISPOS, V28, P945
[4]   Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen [J].
Dasaradhi, L ;
Shibutani, S .
CHEMICAL RESEARCH IN TOXICOLOGY, 1997, 10 (02) :189-196
[5]   The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation [J].
Davis, W ;
Venitt, S ;
Phillips, DH .
CARCINOGENESIS, 1998, 19 (05) :861-866
[6]  
Dehal SS, 1997, CANCER RES, V57, P3402
[7]  
Dehal SS, 1996, CANCER RES, V56, P1283
[8]  
Dehal SS, 1999, DRUG METAB DISPOS, V27, P681
[9]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[10]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537